Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
LEOCLAN Co.,Ltd. (7681.T)
Settsu, JP
LEOCLAN Co.,Ltd. operates as a medical equipment trading firm, addressing diverse needs across medical care, welfare, and general health sectors. Its operations are structured into three main divisions: Medical Total Solutions Business, Remote Image Diagnosis Service Business, and School Lunch Business. The Medical Total Solutions Business segment delivers comprehensive services. This includes advisory support for selecting medical equipment, subsequent maintenance, and undertaking interior design, construction, and installation projects for medical facilities, preventive health centers, and nursing care institutions. Additionally, this segment is involved in the sale of medical devices and information systems. Through its Remote Image Diagnosis Service Business, the company facilitates the remote interpretation of imaging data from MRI, CT, and other scans by diagnostic radiology specialists, subsequently providing critical diagnostic information. Finally, the School Lunch Business segment offers a variety of meal services—including regular, therapeutic, and other specialized dietary options—to nursing care and welfare facilities. Established in 2001, LEOCLAN Co.,Ltd. is headquartered in Settsu, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.00% | -6.05% | -14.82% | -18.40% | -21.06% | -24.00% | -26.10% | -9.94% | -16.59% | -31.93% | -31.93% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Equipment & Services: +14.1%+8.5% Q1'26: +42.4% (vs Q1'25)
-
EPS growth Medical - Equipment & Services: +15.4%+12.2% Q1'26: -37.9% (vs Q1'25)
-
FCF margin FCF growth · Medical - Equipment & Services: -3.5%-0.4% Q1'26: -0.8% (vs Q1'25)
-
EBIT margin Medical - Equipment & Services: +1.1%+1.3% ★ Q1'26: +3.7% (vs Q1'25)
-
ROIC Medical - Equipment & Services: +2.4%+16.5% ★ Q1'26: +38.6% (vs Q1'25)
-
Share dilution Medical - Equipment & Services: -2.1%+0.1% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Equipment & Services: 0.31×0.02× ★ Q1'26: 1.91× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Sep 2019 actual |
Sep 2020 actual |
Sep 2021 actual |
Sep 2022 actual |
Sep 2023 actual |
Sep 2024 actual |
Sep 2025 actual |
|---|---|---|---|---|---|---|---|
| Revenue |
36.11B
est: 35.27B (+2.4%)
|
22.00B
est: 26.04B (-15.5%)
|
26.35B
est: 24.39B (+8.0%)
|
29.77B
est: 27.57B (+8.0%)
|
26.63B
est: 25.09B (+6.2%)
|
19.80B
est: 29.95B (-33.9%)
|
21.49B
est: 33.60B (-36.0%)
|
| EBITDA |
1.31B
est: 780.61M (+67.9%)
|
296.79M
est: 576.37M (-48.5%)
|
670.86M
est: 539.81M (+24.3%)
|
747.26M
est: 610.03M (+22.5%)
|
544.73M
est: 555.14M (-1.9%)
|
277.60M
est: 614.70M (-54.8%)
|
378.03M
est: 689.66M (-45.2%)
|
| EBIT |
1.19B
est: 639.85M (+86.0%)
|
204.37M
est: 472.43M (-56.7%)
|
576.06M
est: 442.47M (+30.2%)
|
650.98M
est: 500.03M (+30.2%)
|
440.30M
est: 455.04M (-3.2%)
|
178.11M
est: 495.19M (-64.0%)
|
288.29M
est: 555.57M (-48.1%)
|
| Net Income |
732.96M
est: 730.39M (+0.4%)
|
120.84M
est: 457.01M (-73.6%)
|
390.98M
est: 204.39M (+91.3%)
|
437.05M
est: 540.43M (-19.1%)
|
271.31M
est: 349.88M (-22.5%)
|
136.06M
est: 496.94M (-72.6%)
|
152.78M
est: 597.76M (-74.4%)
|
| SGA |
2.16B
est: 2.58B (-16.4%)
|
2.05B
est: 1.91B (+7.6%)
|
2.16B
est: 1.79B (+20.8%)
|
2.40B
est: 2.02B (+19.2%)
|
2.38B
est: 1.84B (+29.5%)
|
2.44B
est: 2.93B (-16.7%)
|
2.45B
est: 3.29B (-25.4%)
|
| EPS |
125.61
est: 123.17 (+2.0%)
|
20.84
est: 77.07 (-73.0%)
|
66.64
est: 34.47 (+93.3%)
|
74.30
est: 91.13 (-18.5%)
|
46.12
est: 59.00 (-21.8%)
|
23.09
est: 83.80 (-72.4%)
|
25.85
est: 100.80 (-74.4%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-14 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-12 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-11 | B+ | 3/5 | 5/5 | 3/5 | 3/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-08 | B+ | 3/5 | 5/5 | 3/5 | 3/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-07 | B+ | 3/5 | 5/5 | 3/5 | 3/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-30 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-15 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 1/5 | 2/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Atsushi Nishimoto | GM of Management Division & Director | — | male |
| Okitsugu Takeuchi | Chief Executive Officer, President & Representative Director | — | male |
| Satoshi Yamada | GM of the Sales Division & Osaka Sales Division and Director | — | male |
| Seiji Tagami | Executive Officer, GM of Sales Promotion Department, GM of Sales Department 1 & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 7681.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
